---
title: April 2025
date: 2025-04-30
categories: [Newsletters]
tags: [ Clinical Trials, AI, Data Management, Privacy, Efficiency, Personalization]
description: This issue explores recent advancements in artificial intelligence (AI) for clinical research, focusing on how AI is improving trial design, data management, operational efficiency, and patient monitoring, while highlighting the challenges of generalizability, bias, and the need for real-world validation.
---

# Introduction

The integration of artificial intelligence (AI) into clinical research is reshaping the landscape of medical discovery and patient care. This compilation of recent advancements explores how AI is enabling more precise, efficient, and patient-centric approaches across diverse facets of clinical trials. The scope encompasses innovations in advanced trial design, featuring methodologies for understanding heterogeneous treatment effects and optimizing intervention strategies. It also details robust AI-driven solutions for managing sensitive patient data, ensuring privacy, and enhancing data quality and fairness. Concurrently, operational efficiencies are being realized through AI-powered information synthesis, streamlined patient monitoring, and accelerated adverse event detection. The collective findings demonstrate a clear trajectory towards leveraging computational intelligence to accelerate the development and delivery of tailored medical treatments.

# AI for Advanced Clinical Trial Design and Personalization

Artificial intelligence (AI) is rapidly transforming the landscape of clinical trial design and execution, moving beyond traditional methods to enable a more precise, efficient, and patient-centric approach. This revolution is driven by advancements in understanding Heterogeneous Treatment Effects (HTE), sophisticated causal inference methodologies, and the automation of various trial processes, leading to breakthroughs in patient stratification, dose optimization, and protocol generation. The ultimate goal is to tailor interventions, predict outcomes under varying conditions, and identify patient subgroups that benefit most from specific treatments.

## Unveiling Heterogeneous Treatment Effects and Patient Stratification

A fundamental shift in personalized medicine involves moving beyond average treatment effects (ATE) to understand how interventions impact individuals differently, often referred to as Heterogeneous Treatment Effects (HTE). This understanding is critical for identifying optimal patient subgroups and designing targeted therapies.

Several new methodologies are advancing HTE estimation and patient stratification. The **Model-Agnostic Optimal Subgroup Identification with Multi-Constraint (MOSIC)** framework offers a unified approach to identify patient subgroups that would most benefit from a treatment, incorporating practical constraints like minimum subgroup size and confounder balance simultaneously [1]. By reformulating this combinatorial problem as an unconstrained min-max optimization, MOSIC enhances the reliability and actionability of identified subgroups, contributing to more efficient clinical trial designs. However, its performance is sensitive to learning rate tuning, and it relies on standard causal inference assumptions like Stable Unit Treatment Value Assumption (SUTVA), unconfoundedness, and overlap [1].

Complementing this, a novel pretraining strategy for estimating Conditional Average Treatment Effects (CATEs) leverages the relationship between factors predicting baseline risk and treatment response [2]. This approach, integrated into the R-learner framework, exploits synergies between risk prediction and causal effect estimation, enhancing accuracy in CATE estimation and improving the detection of treatment heterogeneity. This is particularly valuable when prognostic and predictive factors share common underlying pathways, though its benefits diminish with minimal overlap between these factors [2]. The need to translate CATE estimates into actionable decisions is further emphasized by research highlighting that CATE estimators, while accurate for estimation, can be suboptimal for decision-making if they prioritize accuracy in irrelevant regions [2].

For interpretable HTE estimation, **Dynamic Regularized Causal Boosted Decision Trees (CBDT)** offers an efficient method for identifying patient subgroups that benefit most from an intervention, directly yielding interpretable rules [3]. CBDT integrates variance regularization and ATE calibration into a gradient boosted decision tree framework, dynamically updating regularization parameters to balance bias-variance trade-off. This capability can optimize patient selection and personalize treatment strategies, potentially reducing sample sizes needed for statistical significance. Yet, its performance hinges on the unconfoundedness assumption and can be sensitive to learning rate parameters [3].

Extending HTE estimation to multi-arm trials, a **Causal Rule Ensemble Approach** provides an interpretable machine learning framework that maintains predictive accuracy while identifying key factors influencing treatment effects [4]. This rule-based ensemble approach can identify patient subgroups that may benefit most from a given treatment arm, thereby improving trial design and treatment effect evaluation. Its main limitation lies in potentially not fully capturing complex nonlinear HTE due to its additive model structure [4].

For non-targeted trials, where distinct treatment effects on different subgroups might be "tangled," the **PCM (pre-cluster and merge)** method offers an efficient nonparametric approach to estimate group effects [5]. By smoothing individual treatment effects, PCM aims to optimize treatment effects on specific patient populations and identify potential inequities. A key limitation is its reliance on synthetic data for validation, and its performance is sensitive to the quality of counterfactual estimation [5]. The broader challenge of integrating data from studies with disparate outcome measures also needs careful consideration to avoid bias [27].

The interpretability of these models is crucial for clinical adoption. **RuleSHAP**, a framework combining tree ensembles with Bayesian regression, detects and infers complex non-linearities and interactions to identify subpopulations with differential treatment responses [6]. This allows for personalized treatment effects and can inform trial design by uncovering risk and protective factors. However, RuleSHAP's computational demands can be prohibitive for large-scale trials, and its interpretations are dataset-specific [6]. This aligns with general efforts to identify predictive biomarkers via CATE modeling using Shapley Values [5]. Furthermore, research emphasizes preventing spurious variable interactions in treatment effect estimation by integrating knowledge of data generation processes, enhancing model robustness even with imperfect causal models [1].

Beyond individual treatment effects, methods are emerging to estimate effects of multiple treatments and their interactions, and to learn individualized treatment rules (ITRs) [15, 6]. Techniques like Doubly Robust Machine Learning (DML) for multiple treatments and calibration-weighted treatment fusion procedures address challenges of data sparsity and unbalanced covariate distributions, ensuring robust estimation and latent group recovery. Additionally, methods are being developed to estimate ITRs that not only maximize reward but also control harm rates, a critical consideration in high-stakes medical domains [23].

## Optimizing Clinical Trial Operations: From Dose-Finding to Protocol Automation

AI is also streamlining the operational aspects of clinical trials, from determining optimal dosages to automating complex protocol generation.

In Phase I cancer clinical trials, accurately estimating the Maximum Tolerated Dose (MTD) is paramount. A novel **dose-finding design based on Level Set Estimation (LSE)** addresses this by framing MTD estimation as an LSE problem, integrating uncertainty and safety considerations through a unique acquisition function [7]. Simulations suggest this LSE-based design improves MTD selection accuracy and reduces overdose risk compared to traditional methods. However, its current validation relies on simulations and specific prior information, requiring further real-world experimentation and parameter calibration [7].

Clinical trials often face challenges from unforeseen shifts in treatment patterns or data distributions. **Semiparametric Counterfactual Regression** is designed to improve decision-making in such scenarios by predicting outcomes under hypothetical conditions, allowing for better understanding and adjustment to treatment shifts [8]. This doubly robust estimator facilitates adaptable trial designs, though it assumes binary intervention and consistency, limiting applicability to more complex, real-world multi-treatment schemes [8]. This aligns with efforts to capture and adapt to temporal dataset shifts in causal effect estimation for continuous interventions [12].

At a more granular level, AI is being applied to predict drug responses from single-cell data. The **Conditional Monge Gap (CMonge)** offers a promising framework for modeling single-cell perturbation responses, even for unseen drugs and dosages [9]. By predicting how cells respond to various treatments, CMonge can accelerate drug discovery, inform patient selection, and optimize trial designs by modeling cellular heterogeneity. Practical challenges include its reliance on high-quality, large-scale single-cell data, model complexity, and the generalization from *in vitro* cell line data to *in vivo* patient responses [9].

To address the common issue of delayed reward feedback in clinical trials—where treatment effects take time to manifest—algorithms like **Delayed NeuralUCB and Delayed NeuralTS** are being developed within the neural contextual bandit framework [10]. These algorithms adapt treatment strategies in real-time by learning from delayed patient responses, potentially accelerating trials by optimizing patient allocation. However, their current experimental validation uses relatively simplistic reward models and non-clinical datasets, necessitating more complex real-world simulations and validations to fully capture clinical nuances, including heterogeneous treatment effects and complex interactions [10].

Beyond predictive models, AI is also enhancing the automation of trial processes. A novel framework for **Hierarchically Encapsulated Representation for Protocol Design** aims to create structured, machine-readable representations of experimental protocols using Domain-Specific Languages (DSLs) [11]. This can automate protocol design, reduce manual effort, and enhance reproducibility, allowing researchers to focus on strategic aspects. Its limitations include domain specificity, reliance on Large Language Models (LLMs) which can introduce biases or "hallucinated" dependencies, and the continued need for manual certification by domain experts [11]. Furthermore, active learning strategies are being explored to enable data-efficient treatment effect estimation, particularly when labeling treatment outcomes is costly, by formalizing the problem through factual and counterfactual covering perspectives [30].

## Advancing Causal Inference for Robustness and Interpretability

The bedrock of advanced clinical trial design is robust causal inference, which is continuously being refined to address challenges like confounding, missing data, and privacy.

Addressing hidden confounding and covariate mismatch in observational studies, a **Representation Learning approach** proposes neural architectures that learn valid adjustment sets while satisfying covariate matching constraints [12]. This can lead to more accurate treatment effect estimates, informing trial decisions and patient selection. Its applicability is contingent on the availability of partial structural knowledge, such as an anchor variable [12]. Similarly, the **Two-Stage Interpretable Matching (TIM)** framework improves causal inference from observational data by constructing treatment and control groups with similar covariate distributions, reducing bias [13]. TIM iteratively refines matching, though its current scope is limited to binary treatments and does not consider longitudinal data or potential biases from self-reported information [13]. The broader field is actively developing methods for deconfounded warm-start Thompson Sampling to leverage observational data for adaptive clinical trials [17], and density ratio-free doubly robust proxy causal learning for situations with unobserved confounders but available proxies [29]. Challenges like selection bias in experimental data are also being addressed through counterfactual logic to recover unbiased distributions [26].

Privacy is a growing concern in healthcare. New model-agnostic frameworks are emerging for **Differentially Private Causal Inference**, allowing for the estimation of average treatment effects (ATE) without strong structural assumptions while ensuring privacy [9, 14]. These methods decouple nuisance estimation from privacy protection, enabling the use of flexible black-box models and supporting meta-analysis of multiple private ATE estimates. Furthermore, federated learning approaches are being developed for **Federated Causal Inference** from multi-site observational data, addressing privacy and logistical constraints by exchanging aggregate statistics instead of individual-level data, which is crucial for multi-institutional clinical collaborations [3].

Interpretability and understanding the internal mechanisms of AI models are crucial for trust and adoption in clinical settings. Beyond RuleSHAP and CBDT, which provide interpretable rules, Large Language Models (LLMs) are being explored to assist expert elicitation for constructing **Bayesian Networks (BNs)**, aiming to improve the efficiency and transparency of causal model building [14]. LLM-generated BNs have shown lower entropy, suggesting higher confidence, though they are prone to contextual constraints, hallucinated dependencies, and inherited biases [14]. Complementing this, **Mechanistic Interpretability (MI)** techniques are being applied to Neural Networks (NNs) in bio-statistics to validate and understand their internal representations in causal contexts [15]. MI aims to discover computational pathways, identify confounder handling, and compare model mechanisms, thereby enhancing the trustworthiness and explainability of AI methods for causal effect identification. However, the current demonstrations are primarily on synthetic data, and their generalization to complex real-world clinical data requires further validation [15].

Finally, the design of interventions themselves is being optimized. An **Adaptive Integer Programming (IP) approach** is proposed for intervention design, strategically selecting experiments to efficiently uncover causal relationships in clinical trials [16]. This approach minimizes the number of experiments while maximizing information gain and accounting for budgetary constraints. While effective in simulations, it relies on assumptions like a perfect conditional independence oracle and the absence of unobserved confounders, which may not hold in real clinical settings [16]. For **clustered adaptive interventions (cAI)**, a novel M-out-of-N Cluster Bootstrap approach is developed to identify and assess tailoring variables in clustered Sequential Multiple Assignment Randomized Trials (cSMARTs) [17]. This framework allows for constructing reliable confidence intervals for effect moderation parameters, enabling researchers to personalize intervention strategies to the specific needs of different patient populations or clinical settings. However, its current validation uses a relatively simple data-generating mechanism and parametric modeling assumptions, limiting immediate generalizability [17].

# AI-Driven Data Management, Privacy, and Quality Assurance in Clinical Trials

The advancement of Artificial Intelligence (AI) in clinical research hinges on robust data management, stringent privacy protocols, and rigorous quality assurance. Clinical trials inherently involve vast quantities of sensitive patient data, necessitating innovative solutions that facilitate collaborative research while upholding ethical and regulatory standards. This section explores recent AI-driven breakthroughs in privacy-preserving data management and methods for ensuring data quality, debiasing, and fairness in clinical trial applications.

## Privacy-Preserving Collaborative Intelligence

A cornerstone for managing sensitive clinical data is Federated Learning (FL), a decentralized machine learning paradigm that enables collaborative model training across multiple institutions without centralizing raw patient data. As surveyed by Collins and Wang [18], FL addresses critical privacy concerns, allowing institutions to build predictive models for patient selection, treatment response prediction, and adverse event detection on distributed medical data. This approach is vital for adhering to regulations like HIPAA and GDPR [18].

Despite its advantages, FL faces challenges, particularly concerning communication overhead and data heterogeneity, especially when training Large Language Models (LLMs) [18]. To mitigate these issues, novel parameter-efficient FL strategies have emerged. Selective Attention Federated Learning (SAFL), proposed by Li and Zhang [19], dynamically fine-tunes only "attention-critical" transformer layers in LLMs. This selective approach significantly reduces communication bandwidth and enhances differential privacy resilience by limiting the exposure of sensitive parameters. Similarly, "Layer-Skipping Federated Learning" [2] achieves substantial communication cost reduction (approx. 70%) while maintaining high performance. These methods are particularly well-suited for healthcare natural language processing (NLP) tasks where maintaining privacy while maximizing model utility is paramount [19]. The "Federated Healthcare Benchmark (FHBench)" [3] further supports these developments by providing a platform for evaluating efficient and personalized FL frameworks for multimodal healthcare data.

However, FL is not entirely immune to privacy risks. Inference attacks, such as label inference, can still compromise patient privacy even in decentralized settings [5]. To bolster privacy guarantees, differential privacy (DP) is often integrated with FL. "Differential Privacy-Driven Framework" [6] and "Differential Privacy for Deep Learning in Medicine" [7] highlight how DP introduces calibrated noise during model training to ensure statistical privacy, enabling insights extraction without compromising individual patient data. This integration is crucial for fine-tuning LLMs on sensitive medical texts, as demonstrated by studies on radiology report classification that leverage Differentially Private Low-Rank Adaptation (DP-LoRA) [17], and by "Improved Algorithms for Differentially Private Language Model Alignment" [14], which explores DP-AdamW for enhancing LLM alignment with privacy. The "Privacy-preserving4LLM Benchmarking" framework [21] provides a systematic evaluation of various DP algorithms across different LLM architectures, revealing trade-offs between utility and privacy.

Another promising privacy-preserving technique involves merging pre-trained models rather than fine-tuning on sensitive patient data. PatientDx, a framework proposed by Lovón-Melgarejo et al. [20], directly addresses data leakage by merging existing LLMs, aiming to prevent exposure of confidential information. This approach accelerates LLM application in healthcare by reducing the need for extensive data annotation and fine-tuning, offering a pathway for ethical AI deployment in clinical trials for tasks like patient selection or outcome prediction [20].

## Synthetic Data Generation for Data Scarcity and Diversity

Synthetic data generation is increasingly vital for addressing data scarcity, enhancing dataset diversity, and providing privacy-preserving alternatives to real patient data. LLMs are proving effective in generating synthetic Electronic Health Records (EHRs) [21]. Lin et al. [21] demonstrated LLMs' proficiency in generating synthetic data for smaller feature sets, which can mitigate privacy concerns and improve data sharing. While promising, challenges remain in preserving realistic distributions and correlations as data dimensionality increases [21]. "A Comprehensive Survey of Synthetic Tabular Data Generation" [4] further details the landscape of generative models, including LLMs and diffusion models, for creating high-fidelity, privacy-preserving samples.

Deep Generative Models (DGMs) extend beyond LLMs, offering diverse capabilities for synthetic data. Salmè et al. [22] introduced an extended "Generative Learning Trilemma" that considers utility, robustness, and privacy in addition to fidelity, diversity, and sampling efficiency for DGM assessment in data-scarce environments. This framework is crucial for selecting appropriate models in clinical settings where data is limited and specific objectives (e.g., high-fidelity images for diagnostics) must be met while preserving privacy [22].

For time-series data, which is common in EHRs, TarDiff, developed by Deng et al. [23], is a novel target-oriented diffusion framework that generates synthetic EHR time series data optimized for downstream clinical machine learning models. By integrating task-specific influence guidance, TarDiff moves beyond simple data distribution replication to generate samples that specifically improve model performance, addressing issues like data scarcity and class imbalance effectively [23]. This approach can significantly improve the quality of synthetic data used to augment clinical trial datasets, leading to more robust models and better trial outcomes. The generation of synthetic data with controlled characteristics, including site-specific variations and subgroup effects, is further supported by the framework proposed by Segal et al. [24]. This capability is critical for systematically validating ML models across diverse healthcare settings and identifying potential biases related to data heterogeneity before real-world deployment [24]. "Boosting Statistic Learning with Synthetic Data from Pretrained Large Models" [25] emphasizes that while generative models can produce vast datasets, filtering for high-quality, impactful samples is essential for effective augmentation. Moreover, "Generating Reliable Synthetic Clinical Trial Data" [19] highlights that hyperparameter optimization and explicit domain constraints are crucial for ensuring synthetic datasets maintain fidelity, utility, and clinical validity.

## Data Quality, Debiasing, and Fairness

Ensuring high data quality, addressing biases, and promoting fairness are paramount for reliable and ethical AI applications in clinical trials. Label noise, a common issue in clinical data due to measurement error or human annotation, can significantly impact model performance. Nagaraj et al. [25] introduced a "regret" metric to assess the instance-level impact of label noise, allowing identification of potentially unreliable predictions. Their methods for uncertainty quantification can improve decision-making in clinical trials by enabling data cleaning and selective prediction, thus enhancing data quality and trial analysis [25].

Bias in data collection, such as under- or over-reporting of adverse events, can distort trial outcomes. The Graph-based Over- and Under-reporting Debiasing (GROUD) algorithm, proposed by Wu et al. [26], uses graph structures to identify and correct these biases. By modeling bias as a smooth signal over a graph based on similarities (e.g., patient characteristics or geographical locations), GROUD can provide more accurate estimates of treatment efficacy and safety profiles, contributing to improved trial design and patient safety [26]. This aligns with broader efforts in "Data Heterogeneity Modeling for Trustworthy Machine Learning" [15] and "Fairness in Graph Learning Augmented with Machine Learning" [12], which highlight the complex interplay of data diversity and model fairness. "NeuBM: Mitigating Model Bias in Graph Neural Networks through Neutral Input Calibration" [22] offers another method for reducing bias in GNNs, particularly in the presence of class imbalance.

Furthermore, handling missing data, particularly monotone missing patterns (where individuals drop out at earlier stages and remain missing), is crucial for accurate long-term treatment effect estimation in clinical trials. Yang et al. [27] addressed this by proposing sequential missingness assumptions for identification and introducing novel estimation methods like SeqMSM and BalanceNet to improve the accuracy and stability of treatment effect estimates despite severe data sparsity [27].

To evaluate fairness comprehensively, Ning et al. [28] developed "seeBias," an R package for assessing and visualizing AI model fairness across classification, calibration, and other performance metrics. This tool enables researchers to uncover biases that might be missed by traditional metrics, contributing to more equitable outcomes and enhanced trust in AI-driven tools used for patient selection or risk prediction in clinical settings [28]. Complementary approaches like FairSHAP [27] also use attribution-based data augmentation to improve both individual and group fairness through transparent mechanisms.

Finally, ensuring data consistency across disparate sources is a significant challenge in large-scale clinical research. De la Torre [29] introduced a scalable system for harmonizing inconsistent units within clinical datasets, integrating BM25, sentence embeddings, and a transformer-based reranker. This system automates and accelerates data preparation, ensuring consistency across different sources, thereby enhancing the reliability and reproducibility of trial analyses and facilitating the integration of diverse data types such as laboratory results [29]. Such harmonization efforts are critical for enabling multi-institutional studies and meta-analyses, ultimately leading to more statistically powerful and generalizable clinical trial results. The emergence of tools like "FAST: Federated Active Learning with Foundation Models" [30] further streamlines data labeling and model training by reducing communication overhead, particularly in cross-silo scenarios with limited annotation budgets.

These integrated AI solutions for data management, privacy, and quality assurance are propelling clinical trials towards greater efficiency, reliability, and ethical integrity, paving the way for more impactful and equitable healthcare advancements.

# Streamlining Clinical Operations and Enhancing Monitoring with AI

The increasing complexity and cost of clinical trials necessitate innovative approaches to optimize operational efficiency, enhance patient safety, and accelerate the translation of research into clinical practice. Artificial intelligence (AI), particularly large language models (LLMs) and advanced machine learning (ML) techniques, is emerging as a transformative force in achieving these goals. This section explores how AI is revolutionizing day-to-day clinical trial operations, from automating literature review and accelerating adverse event detection to improving patient engagement and leveraging predictive analytics for risk stratification and triage.

## AI-Powered Information Synthesis and Knowledge Generation

Efficient evidence synthesis and information retrieval are foundational to clinical research. The exponential growth in scientific literature has created a critical demand for automated solutions [31]. Automated Meta-Analysis (AMA) leverages natural language processing (NLP) and machine learning to streamline data processing, such as data extraction and statistical modeling, in systematic reviews [31]. While AMA significantly reduces the time and resources needed for evidence synthesis, full end-to-end automation, particularly for advanced stages like heterogeneity and bias assessment, remains an ongoing challenge [31]. This aligns with broader efforts in Natural Language Processing in Support of Evidence-based Medicine (EBM), which seeks to refine evidence extraction, synthesis, and summarization [25].

Beyond traditional literature review, AI tools are enhancing "horizon scanning" to identify emerging healthcare technologies and innovations relevant to clinical trials. Tools like SCANAR and AIDOC automate data retrieval and prioritization, accelerating the identification of innovations that could impact trial design, patient recruitment, or data analysis [32]. AIDOC, for instance, can reduce manual review efforts significantly by reordering textual data based on relevancy, although expert validation remains essential [32].

To address the scarcity of high-quality, domain-specific annotated scientific corpora for LLM training, frameworks like m-KAILIN are proposed. This multi-agent system automatically generates high-quality question-answer pairs from scientific literature, guided by the Medical Subject Headings (MeSH) hierarchy [33]. This distillation of complex biomedical knowledge allows LLMs to better understand medical concepts, streamlining information retrieval and knowledge synthesis for tasks like literature review and data extraction in clinical trials [33]. However, the reliance on MeSH and PubMed introduces potential biases and the quality of the generated datasets depends on the base LLMs used [33]. The promise of LLMs in medical text summarization is also highlighted by frameworks that integrate context-preserving token filtering with knowledge graphs to improve linguistic coherence and clinical fidelity [5]. These approaches underline the critical need for accurate and context-aware processing of unstructured clinical data to inform timely decision-making [5].

The development of robust benchmarks is crucial for evaluating LLM performance in clinical settings. BRIDGE, a multilingual benchmark, assesses LLMs' ability to extract information from diverse real-world Electronic Health Record (EHR) data, improving their applicability for clinical trials across various patient populations and settings [34]. Similarly, the MIMIC-IV-Ext-22MCTS dataset provides a large-scale, time-series clinical event corpus, enabling improved automated patient screening, treatment response prediction, and clinical trial matching systems [35]. However, the generalizability of models trained on single-source datasets like MIMIC-IV remains a limitation due to variations in clinical practices and data documentation [35]. The broader field is also seeing the development of multilingual benchmarks for Arabic medical tasks [8, 19, 20], emphasizing the need for high-quality, diverse datasets to ensure equitable LLM deployment in healthcare. Patient record linkage, critical for integrating fragmented healthcare data, can also be automated by language models, enhancing efficiency by reducing manual efforts in disease surveillance and research [12].

## Enhancing Patient Monitoring and Engagement

AI is directly impacting patient engagement and monitoring within trials. Automating patient interactions, such as phone surveys, can reduce costs, increase scalability, and minimize interviewer bias in data collection [36]. A framework utilizing an AI agent for conducting surveys and another LLM for analyzing transcripts demonstrated high accuracy (98%) in extracting survey data, streamlining patient screening, monitoring, and adherence assessment [36]. While promising for larger and more diverse participant pools, the current reliance on fictitious personas and occasional difficulty with nuanced answers highlights areas for improvement [36].

Medication adherence, a critical factor in trial success, is also being addressed through AI. A multi-scale modeling approach integrates dynamic (recent medication patterns) and static (demographic, psychological, environmental) factors to predict adherence with high accuracy (87.25% daily, 76.04% weekly) [37]. This enables targeted interventions, such as personalized reminders within clinical trials, to improve patient outcomes and trial reliability. Limitations include small sample size, reliance on self-reported data, and generalizability across diverse patient populations [37].

## Accelerating Adverse Event Detection and Pharmacovigilance

Timely and accurate detection of adverse events (AEs) is paramount for patient safety and trial integrity. The IC SSM (Information Component Semantic Similarity Measure) method enhances AE detection in spontaneous reporting systems by incorporating semantic similarity, allowing for more nuanced information sharing and earlier signal detection compared to traditional methods [38]. This approach identifies more true positives and detects signals sooner, directly improving pharmacovigilance in clinical trials [38].

Similarly, the TACO (Task as Context) prompting framework unifies symptom extraction and linking within LLMs for accurate medical symptom coding from unstructured clinical text, such as vaccine safety reports [39]. By embedding task-specific context into the prompt, TACO improves accuracy and efficiency, streamlining the identification and analysis of AEs. However, the framework's generalizability is limited by its focus on vaccine safety reports and its dependence on LLM capabilities and potential biases [39]. LLMs are also showing promise in tasks like drug overdose prediction from longitudinal medical records, outperforming traditional models even in zero-shot settings [13]. Efforts to detect substance use behaviors in clinical notes have also seen significant enhancement with fine-tuned LLMs, achieving high F1-scores for various substance categories, though scalability remains a consideration [29].

## Predictive Modeling for Risk, Triage, and Trial Efficiency

AI-driven predictive models are vital for optimizing patient risk assessment, triage, and overall trial efficiency. Foundation Models (FMs) trained on Electronic Health Records (EHRs) demonstrate strong performance on various clinical prediction tasks, such as predicting inpatient mortality and ICU admission [40]. While FMs show promise, transferability across different healthcare systems can lead to performance degradation, highlighting the need for fine-tuning on local data to ensure robustness [40]. This aligns with research demonstrating the value of integrating domain knowledge from clinical notes into EHR-based pipelines to enhance predictive accuracy for tasks like hospital readmission [15]. The focus on real-world EHR data for predictive modeling is also evident in efforts to predict health outcomes like hospital readmissions and length of stay, with ensemble and deep learning methods showing enhanced accuracy and interpretability [28].

For clinical triage, machine learning models like LGBMClassifier and CatBoostClassifier can accurately predict triage outcomes even with incomplete patient data, enhancing patient screening and real-time decision-making in trials [41]. This could lead to more efficient patient enrollment and reduced workload for medical staff [41]. LLMs also show superior robustness in clinical triage, especially when handling complex data and distribution shifts [42]. However, biases in LLMs, particularly intersectional biases related to sex and race, necessitate careful consideration and mitigation strategies to prevent skewed results in clinical trials [42, 2]. The importance of interpretability in high-stakes decision-making in healthcare is further emphasized by research exploring methods like Chain-of-Thought (CoT) prompting and neurosymbolic models to bridge the trust gap between AI and clinicians [17, 23].

In the context of rare events, which are common in clinical trials, the reliability of prediction metrics like Area Under the Receiver Operating Characteristic curve (AUC) is driven by the *effective sample size* (number of events) rather than the event rate itself [43]. This critical insight guides trial design, emphasizing the need to ensure sufficient event counts to obtain reliable model assessments, particularly for rare outcomes [43].

Furthermore, interpretable non-linear survival regression models using evolutionary symbolic regression can predict time-to-event data (e.g., patient survival) while providing insights into underlying relationships between patient characteristics and outcomes [44]. This transparency can aid in optimizing trial design and treatment selection [44]. For infectious disease trials, the Causal Spatiotemporal Graph Neural Network (CSTGNN) framework offers accurate epidemic spread forecasting by integrating domain-specific knowledge with data-driven techniques, optimizing trial site selection and resource allocation [45].

AI is also being developed to automate and interpret clinical trial predictions more broadly. Frameworks like AutoCT combine LLM reasoning with classical machine learning to generate and refine tabular features from public information, offering scalable and interpretable predictions [30]. Beyond structured data, the ability of LLMs to process long textual data from patient records for overdose prediction further demonstrates their utility in clinical decision support [13].

## Overarching Themes and Future Directions

Across these diverse applications, several recurring themes and challenges emerge. The reliance on LLMs introduces dependencies on model capabilities and inherent biases. While LLMs offer powerful capabilities, concerns about factual accuracy, language-specific limitations, and the reliability of reasoning explanations persist [23, 31]. The transition from general-purpose LLMs to domain-specific models like TxGemma, designed for therapeutic development, is a crucial step towards more efficient and agentic AI systems that predict therapeutic properties and adverse events, offering interactive reasoning and explainability [46]. Similarly, the rise of Small Language Models (SLMs) addresses concerns around data privacy and limited resources, offering scalable and clinically viable solutions for resource-constrained environments [1].

The generalizability of AI models across different datasets and clinical settings remains a significant hurdle. Many studies acknowledge limitations related to dataset specificity, computational resources, and the need for rigorous real-world validation [32, 41, 37]. Furthermore, while AI streamlines data extraction and analysis, the need for human oversight and expert validation is consistently emphasized; these tools assist rather than replace clinical judgment [32, 42]. Addressing biases inherent in training data and ensuring fairness across demographic subgroups is also a critical ethical consideration for equitable AI deployment in healthcare [42, 2]. The challenge of extracting symptoms from unstructured clinical notes also highlights the need for diverse, high-quality training datasets and robust annotation processes to enhance LLMs’ performance and reliability [24].

In conclusion, AI is rapidly transforming clinical operations and monitoring by automating laborious tasks, enhancing predictive capabilities, and providing deeper insights into complex clinical data. From accelerating evidence synthesis and adverse event detection to personalizing patient engagement and optimizing trial design, AI promises more efficient, safer, and faster trial execution. Future research must focus on overcoming current limitations related to generalizability, interpretability, bias mitigation, and robust validation in real-world clinical environments to fully realize AI's transformative potential in advancing medical research and improving patient care.

# Conclusion

The advancements detailed across intelligent clinical trial design, privacy-preserving data management, and operational streamlining collectively illustrate a shift towards more precise and efficient clinical research. Insights into heterogeneous treatment effects facilitate personalized interventions and optimized trial methodologies. Simultaneously, the development of robust federated learning frameworks and synthetic data generation techniques addresses critical concerns regarding data privacy and accessibility. Operational enhancements, including automated information synthesis and predictive modeling for patient monitoring, further support expedited trial execution. While these contributions signify progress, a consistent theme across the findings is the ongoing challenge of ensuring generalizability across diverse clinical settings, mitigating inherent biases, and providing robust real-world validation. Continued efforts to address these areas will be instrumental in translating these AI-driven innovations into widespread clinical utility, ultimately accelerating the discovery and deployment of effective, tailored therapies.

# References

1.  Wenxin Chen, Weishen Pan, Kyra Gan, Fei Wang (2025). *MOSIC: Model-Agnostic Optimal Subgroup Identification with Multi-Constraint for Improved Reliability*. ArXiv:2504.20908v1. [http://arxiv.org/pdf/2504.20908v1](http://arxiv.org/pdf/2504.20908v1)
2.  Maximilian Schuessler, Erik Sverdrup, Robert Tibshirani (2025). *Statistical Learning for Heterogeneous Treatment Effects: Pretraining, Prognosis, and Prediction*. ArXiv:2505.00310v1. [http://arxiv.org/pdf/2505.00310v1](http://arxiv.org/pdf/2505.00310v1)
3.  Yichen Liu (2025). *Dynamic Regularized CBDT: Variance-Calibrated Causal Boosting for Interpretable Heterogeneous Treatment Effects*. ArXiv:2504.13733v1. [http://arxiv.org/pdf/2504.13733v1](http://arxiv.org/pdf/2504.13733v1)
4.  Ke Wan, Kensuke Tanioka, Toshio Shimokawa (2025). *Causal rule ensemble approach for multi-arm data*. ArXiv:2504.17166v1. [http://arxiv.org/pdf/2504.17166v1](http://arxiv.org/pdf/2504.17166v1)
5.  Georgios Mavroudeas, Malik Magdon-Ismail, Kristin P. Bennett, Jason Kuruzovich (2025). *Consistent Causal Inference of Group Effects in Non-Targeted Trials with Finitely Many Effect Levels*. ArXiv:2504.15854v1. [http://arxiv.org/pdf/2504.15854v1](http://arxiv.org/pdf/2504.15854v1)
6.  Giorgio Spadaccini, Marjolein Fokkema, Mark A. van de Wiel (2025). *Hypothesis-free discovery from epidemiological data by automatic detection and local inference for tree-based nonlinearities and interactions*. ArXiv:2505.00571v1. [http://arxiv.org/pdf/2505.00571v1](http://arxiv.org/pdf/2505.00571v1)
7.  Keiichiro Seno, Kota Matsui, Shogo Iwazaki, Yu Inatsu, Shion Takeno, Shigeyuki Matsui (2025). *Dose-finding design based on level set estimation in phase I cancer clinical trials*. ArXiv:2504.09157v1. [http://arxiv.org/pdf/2504.09157v1](http://arxiv.org/pdf/2504.09157v1)
8.  Kwangho Kim (2025). *Semiparametric Counterfactual Regression*. ArXiv:2504.02694v2. [http://arxiv.org/pdf/2504.02694v2](http://arxiv.org/pdf/2504.02694v2)
9.  Alice Driessen, Benedek Harsanyi, Marianna Rapsomaniki, Jannis Born (2025). *Towards generalizable single-cell perturbation modeling via the Conditional Monge Gap*. ArXiv:2504.08328v1. [http://arxiv.org/pdf/2504.08328v1](http://arxiv.org/pdf/2504.08328v1)
10. Mohammadali Moghimi, Sharu Theresa Jose, Shana Moothedath (2025). *Neural Contextual Bandits Under Delayed Feedback Constraints*. ArXiv:2504.12086v1. [http://arxiv.org/pdf/2504.12086v1](http://arxiv.org/pdf/2504.12086v1)
11. Yu-Zhe Shi, Mingchen Liu, Fanxu Meng, Qiao Xu, Zhangqian Bi, Kun He, Lecheng Ruan, Qining Wang (2025). *Hierarchically Encapsulated Representation for Protocol Design in Self-Driving Labs*. ArXiv:2504.03810v1. [http://arxiv.org/pdf/2504.03810v1](http://arxiv.org/pdf/2504.03810v1)
12. Praharsh Nanavati, Ranjitha Prasad, Karthikeyan Shanmugam (2025). *Representation Learning Preserving Ignorability and Covariate Matching for Treatment Effects*. ArXiv:2504.20579v1. [http://arxiv.org/pdf/2504.20579v1](http://arxiv.org/pdf/2504.20579v1)
13. Sahil Shikalgar, Md. Noor-E-Alam (2025). *A Two-Stage Interpretable Matching Framework for Causal Inference*. ArXiv:2504.09635v1. [http://arxiv.org/pdf/2504.09635v1](http://arxiv.org/pdf/2504.09635v1)
14. Olha Shaposhnyk, Daria Zahorska, Svetlana Yanushkevich (2025). *Can LLMs Assist Expert Elicitation for Probabilistic Causal Modeling?*. ArXiv:2504.10397v1. [http://arxiv.org/pdf/2504.10397v1](http://arxiv.org/pdf/2504.10397v1)
15. Jean-Baptiste A. Conan (2025). *On the Mechanistic Interpretability of Neural Networks for Causality in Bio-statistics*. ArXiv:2505.00555v1. [http://arxiv.org/pdf/2505.00555v1](http://arxiv.org/pdf/2505.00555v1)
16. Abdelmonem Elrefaey, Rong Pan (2025). *From Observation to Orientation: an Adaptive Integer Programming Approach to Intervention Design*. ArXiv:2504.03122v2. [http://arxiv.org/pdf/2504.03122v2](http://arxiv.org/pdf/2504.03122v2)
17. Yao Song, Kelly Speth, Amy Kilbourne, Andrew Quanbeck, Daniel Almirall, Lu Wang (2025). *Q-Learning with Clustered-SMART (cSMART) Data: Examining Moderators in the Construction of Clustered Adaptive Interventions*. ArXiv:2505.00822v1. [http://arxiv.org/pdf/2505.00822v1](http://arxiv.org/pdf/2505.00822v1)
18. Edward Collins, Michel Wang (2025). *Federated Learning: A Survey on Privacy-Preserving Collaborative Intelligence*. ArXiv:2504.17703v1. [http://arxiv.org/pdf/2504.17703v1](http://arxiv.org/pdf/2504.17703v1)
19. Yue Li, Lihong Zhang (2025). *Selective Attention Federated Learning: Improving Privacy and Efficiency for Clinical Text Classification*. ArXiv:2504.11793v2. [http://arxiv.org/pdf/2504.11793v2](http://arxiv.org/pdf/2504.11793v2)
20. Jose G. Moreno, Jesus Lovon, M'Rick Robin-Charlet, Christine Damase-Michel, Lynda Tamine (2025). *PatientDx: Merging Large Language Models for Protecting Data-Privacy in Healthcare*. ArXiv:2504.17360v1. [http://arxiv.org/pdf/2504.17360v1](http://arxiv.org/pdf/2504.17360v1)
21. Yihan Lin, Zhirong Bella Yu, Simon Lee (2025). *A Case Study Exploring the Current Landscape of Synthetic Medical Record Generation with Commercial LLMs*. ArXiv:2504.14657v1. [http://arxiv.org/pdf/2504.14657v1](http://arxiv.org/pdf/2504.14657v1)
22. Marco Salmè, Lorenzo Tronchin, Rosa Sicilia, Paolo Soda, Valerio Guarrasi (2025). *Beyond the Generative Learning Trilemma: Generative Model Assessment in Data Scarcity Domains*. ArXiv:2504.10555v1. [http://arxiv.org/pdf/2504.10555v1](http://arxiv.org/pdf/2504.10555v1)
23. Bowen Deng, Chang Xu, Hao Li, Yuhao Huang, Min Hou, Jiang Bian (2025). *TarDiff: Target-Oriented Diffusion Guidance for Synthetic Electronic Health Record Time Series Generation*. ArXiv:2504.17613v1. [http://arxiv.org/pdf/2504.17613v1](http://arxiv.org/pdf/2504.17613v1)
24. Bradley Segal, Joshua Fieggen, David Clifton, Lei Clifton (2025). *Bridging the Generalisation Gap: Synthetic Data Generation for Multi-Site Clinical Model Validation*. ArXiv:2504.20635v1. [http://arxiv.org/pdf/2504.20635v1](http://arxiv.org/pdf/2504.20635v1)
25. Sujay Nagaraj, Yang Liu, Flavio P. Calmon, Berk Ustun (2025). *Regretful Decisions under Label Noise*. ArXiv:2504.09330v1. [http://arxiv.org/pdf/2504.09330v1](http://arxiv.org/pdf/2504.09330v1)
26. Dongze Wu, Hanyang Jiang, Yao Xie (2025). *Graph-Based Prediction Models for Data Debiasing*. ArXiv:2504.09348v1. [http://arxiv.org/pdf/2504.09348v1](http://arxiv.org/pdf/2504.09348v1)
27. Qinwei Yang, Ruocheng Guo, Shasha Han, Peng Wu (2025). *Identification and Estimation of Long-Term Treatment Effects with Monotone Missing*. ArXiv:2504.19527v1. [http://arxiv.org/pdf/2504.19527v1](http://arxiv.org/pdf/2504.19527v1)
28. Yilin Ning, Yian Ma, Mingxuan Liu, Xin Li, Nan Liu (2025). *seeBias: A Comprehensive Tool for Assessing and Visualizing AI Fairness*. ArXiv:2504.08418v1. [http://arxiv.org/pdf/2504.08418v1](http://arxiv.org/pdf/2504.08418v1)
29. Jordi de la Torre (2025). *Scalable Unit Harmonization in Medical Informatics Using Bi-directional Transformers and Bayesian-Optimized BM25 and Sentence Embedding Retrieval*. ArXiv:2505.00810v1. [http://arxiv.org/pdf/2505.00810v1](http://arxiv.org/pdf/2505.00810v1)
30. Haoyuan Li, Mathias Funk, Jindong Wang, Aaqib Saeed (2025). *FAST: Federated Active Learning with Foundation Models for Communication-efficient Sampling and Training*. ArXiv:2504.03783v2. [http://arxiv.org/pdf/2504.03783v2](http://arxiv.org/pdf/2504.03783v2)
31. Lingbo Li, Anuradha Mathrani, Teo Susnjak (2025). *Transforming Evidence Synthesis: A Systematic Review of the Evolution of Automated Meta-Analysis in the Age of AI*. ArXiv:2504.20113v1. [http://arxiv.org/pdf/2504.20113v1](http://arxiv.org/pdf/2504.20113v1)
32. Lena Schmidt, Oshin Sharma, Chris Marshall, Sonia Garcia Gonzalez Moral (2025). *Horizon Scans can be accelerated using novel information retrieval and artificial intelligence tools*. ArXiv:2504.01627v1. [http://arxiv.org/pdf/2504.01627v1](http://arxiv.org/pdf/2504.01627v1)
33. Meng Xiao, Xunxin Cai, Chengrui Wang, Yuanchun Zhou (2025). *m-KAILIN: Knowledge-Driven Agentic Scientific Corpus Distillation Framework for Biomedical Large Language Models Training*. ArXiv:2504.19565v1. [http://arxiv.org/pdf/2504.19565v1](http://arxiv.org/pdf/2504.19565v1)
34. Jiageng Wu, Bowen Gu, Ren Zhou, Kevin Xie, Doug Snyder, Yixing Jiang, Valentina Carducci, Richard Wyss, Rishi J Desai, Emily Alsentzer, Leo Anthony Celi, Adam Rodman, Sebastian Schneeweiss, Jonathan H. Chen, Santiago Romero-Brufau, Kueiyu Joshua Lin, Jie Yang (2025). *BRIDGE: Benchmarking Large Language Models for Understanding Real-world Clinical Practice Text*. ArXiv:2504.19467v2. [http://arxiv.org/pdf/2504.19467v2](http://arxiv.org/pdf/2504.19467v2)
35. Jing Wang, Xing Niu, Juyong Kim, Jie Shen, Tong Zhang, Jeremy C. Weiss (2025). *MIMIC-\RNum{4}-Ext-22MCTS: A 22 Millions-Event Temporal Clinical Time-Series Dataset with Relative Timestamp for Risk Prediction*. ArXiv:2505.00827v1. [http://arxiv.org/pdf/2505.00827v1](http://arxiv.org/pdf/2505.00827v1)
36. Kurmanbek Kaiyrbekov, Nicholas J Dobbins, Sean D Mooney (2025). *Automated Survey Collection with LLM-based Conversational Agents*. ArXiv:2504.02891v1. [http://arxiv.org/pdf/2504.02891v1](http://arxiv.org/pdf/2504.02891v1)
37. Navreet Kaur, Manuel Gonzales IV, Cristian Garcia Alcaraz, Jiaqi Gong, Kristen J. Wells, Laura E. Barnes (2025). *A computational framework for longitudinal medication adherence prediction in breast cancer survivors: A social cognitive theory based approach*. ArXiv:2504.14469v1. [http://arxiv.org/pdf/2504.14469v1](http://arxiv.org/pdf/2504.14469v1)
38. François Haguinet, Jeffery L Painter, Gregory E Powell, Andrea Callegaro, Andrew Bate (2025). *Bayesian dynamic borrowing considering semantic similarity between outcomes for disproportionality analysis in FAERS*. ArXiv:2504.12052v2. [http://arxiv.org/pdf/2504.12052v2](http://arxiv.org/pdf/2504.12052v2)
39. Chengyang He, Wenlong Zhang, Violet Xinying Chen, Yue Ning, Ping Wang (2025). *Task as Context Prompting for Accurate Medical Symptom Coding Using Large Language Models*. ArXiv:2504.03051v1. [http://arxiv.org/pdf/2504.03051v1](http://arxiv.org/pdf/2504.03051v1)
40. Michael C. Burkhart, Bashar Ramadan, Zewei Liao, Kaveri Chhikara, Juan C. Rojas, William F. Parker, Brett K. Beaulieu-Jones (2025). *Foundation models for electronic health records: representation dynamics and transferability*. ArXiv:2504.10422v1. [http://arxiv.org/pdf/2504.10422v1](http://arxiv.org/pdf/2504.10422v1)
41. Sofia Krylova, Fabian Schmidt, Vladimir Vlassov (2025). *Leveraging Machine Learning Models to Predict the Outcome of Digital Medical Triage Interviews*. ArXiv:2504.11977v1. [http://arxiv.org/pdf/2504.11977v1](http://arxiv.org/pdf/2504.11977v1)
42. Joseph Lee, Tianqi Shang, Jae Young Baik, Duy Duong-Tran, Shu Yang, Lingyao Li, Li Shen (2025). *Investigating LLMs in Clinical Triage: Promising Capabilities, Persistent Intersectional Biases*. ArXiv:2504.16273v1. [http://arxiv.org/pdf/2504.16273v1](http://arxiv.org/pdf/2504.16273v1)
43. Emily Minus, R. Yates Coley, Susan M. Shortreed, Brian D. Williamson (2025). *Behavior of prediction performance metrics with rare events*. ArXiv:2504.16185v1. [http://arxiv.org/pdf/2504.16185v1](http://arxiv.org/pdf/2504.16185v1)
44. Luigi Rovito, Marco Virgolin (2025). *Interpretable Non-linear Survival Analysis with Evolutionary Symbolic Regression*. ArXiv:2504.05756v1. [http://arxiv.org/pdf/2504.05756v1](http://arxiv.org/pdf/2504.05756v1)
45. Shuai Han, Lukas Stelz, Thomas R. Sokolowski, Kai Zhou, Horst Stöcker (2025). *Unifying Physics- and Data-Driven Modeling via Novel Causal Spatiotemporal Graph Neural Network for Interpretable Epidemic Forecasting*. ArXiv:2504.05140v1. [http://arxiv.org/pdf/2504.05140v1](http://arxiv.org/pdf/2504.05140v1)
46. Eric Wang, Samuel Schmidgall, Paul F. Jaeger, Fan Zhang, Rory Pilgrim, Yossi Matias, Joelle Barral, David Fleet, Shekoofeh Azizi (2025). *TxGemma: Efficient and Agentic LLMs for Therapeutics*. ArXiv:2504.06196v1. [http://arxiv.org/pdf/2504.06196v1](http://arxiv.org/pdf/2504.06196v1)
